Personally I think we are all getting a bit too far ahead. I think the idea of the $250 million potential that we can grab when needed is out there for as a stated, growth purposes. The company has stated in the past that they will probably go it alone for Rett and PDD. I have never heard them say anything different. Now keep in mind for those two indications we are only in phase 2. I would have to think that we were going to need a fair chunk of money to do a phase 3 with many more people involved in those trials. That is why we need this potential funding.
As it relates to Harold Hampel, after thinking about this for a while I believe the answer is simple. He now works for a potential competitor or may be a potential partner which creates a conflict of interest. He is no longer on the scientific side of things or academic side of things, he is in it for the money. If you look at everyone else on our scientific advisory board it certainly seems that they are all truly on the research side and not employees of a corporation. I think this makes sense and we now have a strong ally with a potential far east partner.